JP6143767B2 - がん治療用組合せリポソーム組成物 - Google Patents

がん治療用組合せリポソーム組成物 Download PDF

Info

Publication number
JP6143767B2
JP6143767B2 JP2014539143A JP2014539143A JP6143767B2 JP 6143767 B2 JP6143767 B2 JP 6143767B2 JP 2014539143 A JP2014539143 A JP 2014539143A JP 2014539143 A JP2014539143 A JP 2014539143A JP 6143767 B2 JP6143767 B2 JP 6143767B2
Authority
JP
Japan
Prior art keywords
liposome
liposomes
therapeutic
mol
combination according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014539143A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014532665A5 (cg-RX-API-DMAC7.html
JP2014532665A (ja
Inventor
ジュン ヤン，
ジュン ヤン，
スティーブン エイチ． ウー，
スティーブン エイチ． ウー，
クリフ ジェイ． ハーマン，
クリフ ジェイ． ハーマン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mallinckrodt Inc
Original Assignee
Mallinckrodt Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Inc filed Critical Mallinckrodt Inc
Publication of JP2014532665A publication Critical patent/JP2014532665A/ja
Publication of JP2014532665A5 publication Critical patent/JP2014532665A5/ja
Application granted granted Critical
Publication of JP6143767B2 publication Critical patent/JP6143767B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014539143A 2011-10-31 2012-10-31 がん治療用組合せリポソーム組成物 Expired - Fee Related JP6143767B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161553786P 2011-10-31 2011-10-31
US61/553,786 2011-10-31
PCT/US2012/062635 WO2013066903A1 (en) 2011-10-31 2012-10-31 Combinational liposome compositions for cancer therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017044663A Division JP6549172B2 (ja) 2011-10-31 2017-03-09 がん治療用組合せリポソーム組成物

Publications (3)

Publication Number Publication Date
JP2014532665A JP2014532665A (ja) 2014-12-08
JP2014532665A5 JP2014532665A5 (cg-RX-API-DMAC7.html) 2015-09-24
JP6143767B2 true JP6143767B2 (ja) 2017-06-07

Family

ID=47146747

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2014539143A Expired - Fee Related JP6143767B2 (ja) 2011-10-31 2012-10-31 がん治療用組合せリポソーム組成物
JP2017044663A Expired - Fee Related JP6549172B2 (ja) 2011-10-31 2017-03-09 がん治療用組合せリポソーム組成物
JP2018218127A Pending JP2019023243A (ja) 2011-10-31 2018-11-21 がん治療用組合せリポソーム組成物
JP2019088222A Pending JP2019123753A (ja) 2011-10-31 2019-05-08 がん治療用組合せリポソーム組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2017044663A Expired - Fee Related JP6549172B2 (ja) 2011-10-31 2017-03-09 がん治療用組合せリポソーム組成物
JP2018218127A Pending JP2019023243A (ja) 2011-10-31 2018-11-21 がん治療用組合せリポソーム組成物
JP2019088222A Pending JP2019123753A (ja) 2011-10-31 2019-05-08 がん治療用組合せリポソーム組成物

Country Status (12)

Country Link
US (4) US9370489B2 (cg-RX-API-DMAC7.html)
EP (2) EP3424564A1 (cg-RX-API-DMAC7.html)
JP (4) JP6143767B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140097215A (cg-RX-API-DMAC7.html)
CN (1) CN104023793B (cg-RX-API-DMAC7.html)
BR (1) BR112014010291A2 (cg-RX-API-DMAC7.html)
CA (1) CA2852564A1 (cg-RX-API-DMAC7.html)
ES (1) ES2694154T3 (cg-RX-API-DMAC7.html)
IL (2) IL232344B (cg-RX-API-DMAC7.html)
MX (1) MX360391B (cg-RX-API-DMAC7.html)
RU (1) RU2640934C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013066903A1 (cg-RX-API-DMAC7.html)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2768444A1 (en) * 2009-07-17 2011-01-20 Rigshospitalet Loading technique for preparing radionuclide and ionophore containing liposomes in which the ionophore is 2-hydroxyquionoline (carbostyril) or structurally related 2-hydroxyquinolines
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
MX2013003681A (es) 2010-10-01 2013-11-20 Moderna Therapeutics Inc Ácidos nucleicos manipulados y métodos de uso de los mismos.
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
SMT202200355T1 (it) 2011-12-16 2022-11-18 Modernatx Inc Composizioni di mrna modificato
EP2834260A4 (en) 2012-04-02 2016-08-10 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF MEMBRANE PROTEINS
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
PL4332576T3 (pl) 2013-03-15 2025-09-08 Translate Bio, Inc. Synergistyczne wzmocnienie dostarczania kwasów nukleinowych poprzez formulacje zmieszane
JP2014227338A (ja) * 2013-05-17 2014-12-08 キヤノン株式会社 インドシアニングリーン含有粒子およびその製造方法
CA2938626A1 (en) 2013-07-26 2015-01-29 John Rothman Compositions to improve the therapeutic benefit of bisantrene
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
DK3138555T3 (da) 2014-04-30 2020-12-14 Fujifilm Corp Liposomsammensætning og fremgangsmåde til fremstilling heraf
CN107921005A (zh) * 2015-02-13 2018-04-17 友杏生技医药股份有限公司 利用纳米颗粒治疗肿瘤的组合物和方法
WO2016141167A1 (en) 2015-03-03 2016-09-09 Cureport, Inc. Combination liposomal pharmaceutical formulations
US10736845B2 (en) 2015-03-03 2020-08-11 Cureport Inc. Dual loaded liposomal pharmaceutical formulations
WO2016146516A1 (en) * 2015-03-17 2016-09-22 Leon-Nanodrugs Gmbh Nanoparticles comprising a stabilized boronic acid compound
EP3277264A4 (en) * 2015-04-02 2018-07-18 The Research Foundation for the State University of New York Serum-stable compositions and methods for light-triggered release of materials
ES2910425T3 (es) 2015-09-17 2022-05-12 Modernatx Inc Compuestos y composiciones para la administración intracelular de agentes terapéuticos
WO2017078008A1 (ja) * 2015-11-02 2017-05-11 富士フイルム株式会社 ゲムシタビンリポソーム組成物を含む腫瘍治療剤およびキット
EP3377043A4 (en) * 2015-11-20 2019-06-26 The Regents of The University of California DEVICABLE NANOSCAL CARRIER (DNVS) FOR ADMINISTRATION THROUGH THE BLOOD-BRAIN-BARRIER, MICE AND SKIN
WO2017099823A1 (en) 2015-12-10 2017-06-15 Modernatx, Inc. Compositions and methods for delivery of therapeutic agents
US20200282101A1 (en) * 2015-12-18 2020-09-10 Medigear International Corporation Biodegradable tumor sealant
EP4036079B1 (en) 2015-12-22 2025-11-19 ModernaTX, Inc. Compounds and compositions for intracellular delivery of agents
KR101630397B1 (ko) * 2015-12-31 2016-06-24 한국과학기술원 항암제-인도시아닌 그린-리포좀 복합체를 포함하는 암 치료용 조성물
EP3416623B1 (en) 2016-02-15 2021-08-11 University of Georgia Research Foundation, Inc. Ipa-3-loaded liposomes and methods of use thereof
US11266602B2 (en) 2016-05-16 2022-03-08 Infectious Disease Research Institute PEGylated liposomes and methods of use
EP3538067A1 (en) 2016-11-08 2019-09-18 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
CN106474057A (zh) * 2016-12-02 2017-03-08 中国药科大学 一种奥沙利铂热敏长循环脂质体的蔗糖溶液制剂及其制备方法
CN110381922A (zh) * 2017-01-18 2019-10-25 淡马锡生命科学研究院有限公司 超稳定脂质体增加对有丝分裂细胞的靶向作用
RS63953B1 (sr) 2017-03-15 2023-02-28 Modernatx Inc Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava
AU2018234814B2 (en) 2017-03-15 2022-06-30 Modernatx, Inc. Crystal forms of amino lipids
WO2018170336A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Lipid nanoparticle formulation
WO2018232120A1 (en) 2017-06-14 2018-12-20 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
EP3638215A4 (en) 2017-06-15 2021-03-24 Modernatx, Inc. RNA FORMULATIONS
US10925831B2 (en) * 2017-08-28 2021-02-23 Wake Forest University Liposomal formulations of platinum-acridine anticancer agents and methods thereof
CA3073211A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. Methods of making lipid nanoparticles
US11110060B2 (en) * 2017-10-25 2021-09-07 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for delivering pharmaceutical agents
US10606661B2 (en) * 2017-12-15 2020-03-31 Rubrik, Inc. On-demand provisioning of customized developer environments
EP3811949B1 (en) 2018-06-20 2024-07-03 FUJIFILM Corporation Combined medicine comprising gemcitabine-encapsulated liposome composition and immune checkpoint blockade
EP3853202A1 (en) 2018-09-19 2021-07-28 ModernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
EP3852732A1 (en) 2018-09-19 2021-07-28 ModernaTX, Inc. Peg lipids and uses thereof
CN112996854B (zh) 2018-09-19 2024-08-30 摩登纳特斯有限公司 高纯度peg脂质和其用途
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
WO2020115171A1 (en) * 2018-12-06 2020-06-11 Glaxosmithkline Biologicals Sa Immunogenic compositions
RU2706427C1 (ru) * 2018-12-27 2019-11-19 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский технологический университет "МИСиС" Способ лечения онкологических заболеваний с помощью инъекций лекарственного препарата
JP7253735B2 (ja) 2019-07-02 2023-04-07 パナソニックＩｐマネジメント株式会社 通過可否判定装置、通過管理システム、通過可否判定方法、及び、コンピュータプログラム
AR120080A1 (es) 2019-09-19 2022-02-02 Modernatx Inc Compuestos lipídicos de cola ramificada y composiciones para la administración intracelular de agentes terapéuticos
EP4031142A1 (en) 2019-09-19 2022-07-27 Danmarks Tekniske Universitet Immune stimulating micelle composition
US20220364139A1 (en) * 2019-09-24 2022-11-17 Pataigin, Llc Methods for determining growth and response
CN110571005B (zh) * 2019-09-27 2021-01-01 广西科技大学 一种固定化金属离子-磁性脂质体及其制备方法和应用
EP4199906A1 (en) * 2020-08-20 2023-06-28 Bionanosim (BNS) Ltd Lipid delivery systems for delivery of oxaliplatin palmitate acetate
KR102560135B1 (ko) 2020-12-04 2023-07-27 가톨릭대학교 산학협력단 표적 치료제의 효과적인 전달을 위한 다기능성 리포좀 조성물
US20240229154A9 (en) 2021-02-12 2024-07-11 Institut National de la Santé et de la Recherche Médicale Method for prognosis and treating a patient suffering from cancer
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
EP4306126A1 (en) 2021-03-08 2024-01-17 Eyegene Inc. Vaccine composition for preventing sars-cov-2

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023087A (en) * 1986-02-10 1991-06-11 Liposome Technology, Inc. Efficient method for preparation of prolonged release liposome-based drug delivery system
WO1997038010A2 (en) 1996-04-11 1997-10-16 The University Of British Columbia Fusogenic liposomes
US6897196B1 (en) 2001-02-07 2005-05-24 The Regents Of The University Of California pH sensitive lipids based on ortho ester linkers, composition and method
US7273620B1 (en) * 2002-05-20 2007-09-25 University Of British Columbia Triggered release of liposomal drugs following mixing of cationic and anionic liposomes
US7149468B2 (en) 2002-07-25 2006-12-12 The Mcgraw-Hill Companies, Inc. Methods for improving certainty of test-taker performance determinations for assessments with open-ended items
AU2002350719A1 (en) * 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
WO2004103344A1 (en) 2003-05-20 2004-12-02 Aronex Pharmaceuticals, Inc. Combination chemotherapy comprising a liposomal platinum complex
EP1695696A1 (en) * 2003-12-01 2006-08-30 Mitsubishi Pharma Corporation Liposome
TWI262798B (en) * 2003-12-31 2006-10-01 Ind Tech Res Inst Liposome and drug deliver system
US20110020434A1 (en) 2005-09-02 2011-01-27 O'halloran Thomas V Nanoparticle arsenic-platinum compositions
WO2007049279A2 (en) * 2005-10-26 2007-05-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem A liposomal combination and uses thereof

Also Published As

Publication number Publication date
JP2017101085A (ja) 2017-06-08
WO2013066903A1 (en) 2013-05-10
RU2640934C2 (ru) 2018-01-12
CN104023793B (zh) 2017-11-24
ES2694154T3 (es) 2018-12-18
CA2852564A1 (en) 2013-05-10
MX2014004960A (es) 2014-06-05
IL258740A (en) 2018-06-28
KR20140097215A (ko) 2014-08-06
JP2014532665A (ja) 2014-12-08
US20160338958A1 (en) 2016-11-24
US9717686B2 (en) 2017-08-01
EP3424564A1 (en) 2019-01-09
EP2773426A1 (en) 2014-09-10
JP2019123753A (ja) 2019-07-25
US20180015039A1 (en) 2018-01-18
US9370489B2 (en) 2016-06-21
JP2019023243A (ja) 2019-02-14
IL232344A0 (en) 2014-06-30
US20130115273A1 (en) 2013-05-09
US10213385B2 (en) 2019-02-26
EP2773426B1 (en) 2018-08-22
CN104023793A (zh) 2014-09-03
MX360391B (es) 2018-10-31
JP6549172B2 (ja) 2019-07-24
IL258740B (en) 2019-01-14
RU2014120216A (ru) 2015-12-10
BR112014010291A2 (pt) 2017-04-18
US20190175505A1 (en) 2019-06-13
IL232344B (en) 2018-05-31

Similar Documents

Publication Publication Date Title
JP6143767B2 (ja) がん治療用組合せリポソーム組成物
JP6294456B2 (ja) 修飾されたドセタキセルリポソーム製剤
JP5927194B2 (ja) 治療ナノキャリアおよび／または診断ナノキャリアのターゲティングのためのアプタマーコンジュゲート
US20180344644A1 (en) Improved stability of liposome formulations and uses thereof
JP2014528411A (ja) 相補的オリゴヌクレオチドリンカーを用いる標的化ナノ粒子の遠隔アセンブリ
US20160250177A1 (en) Modified docetaxel liposome formulations and uses thereof
US20200079785A1 (en) Mitomycin c prodrug liposome formulations and uses thereof
US20210290537A1 (en) Liposomal elinafide formulations and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150806

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160526

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160912

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170309

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170316

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170413

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170509

R150 Certificate of patent or registration of utility model

Ref document number: 6143767

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees